Therapeutic Drug Monitoring of Mycophenolate Mofeti

Therapeutic Drug Monitoring
28, 145-154
DOI: 10.1097/01.ftd.0000199358.80013.bd

Citation Report

#	Article	IF	Citations
1	A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin Aâ€"Containing and cyclosporin Aâ€"Free immunosuppressive regimens. Clinical Therapeutics, 2006, 28, 893-905.	1.1	18
2	The Role of Therapeutic Drug Monitoring in Individualizing Immunosuppressive Drug Therapy: Recent Developments. Therapeutic Drug Monitoring, 2006, 28, 719-725.	1.0	64
4	CEDIAÂ® Mycophenolic Acid Assay Compared With HPLC-UV in Specimens From Transplant Recipients. Therapeutic Drug Monitoring, 2006, 28, 632-636.	1.0	25
5	Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: Implications for drug exposure in renal allograft recipients. Clinical Pharmacology and Therapeutics, 2006, 80, 509-521.	2.3	73
6	Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. European Journal of Clinical Pharmacology, 2006, 63, 27-37.	0.8	35
7	Pharmacokinetics of Mycophenolic Acid and Its Glucuronidated Metabolites in Stable Lung Transplant Recipients. Annals of Pharmacotherapy, 2006, 40, 1509-1516.	0.9	21
8	Hearing the Voices of Adolescent Boys in Choral Music: A Self-Story. Research Studies in Music Education, 2006, 27, 69-81.	0.8	22
9	Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: association with clinical outcome. Current Medical Research and Opinion, 2006, 22, 2355-2364.	0.9	39
10	Mycophenolate mofetil: long-term outcomes in solid organ transplantation. Expert Review of Clinical Immunology, 2006, 2, 495-518.	1.3	5
11	Therapeutic Drug Monitoring of Mycophenolic Acid. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 1062-1072.	2.2	74
12	C-440T/T-331C polymorphisms in theUGT1A9gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics, 2007, 8, 1127-1141.	0.6	86
13	Therapeutic Monitoring of Mycophenolate Mofetil. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 184-191.	2.2	99
14	Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 251-261.	1.5	32
15	Effects of a Mycophenolate Mofetil-Based Immunosuppressive Regimen in Chagasâ€² Heart Transplant Recipients. Transplantation, 2007, 84, 441-442.	0.5	33
16	The Magnitude and Time Course of Changes in Mycophenolic Acid 12-Hour Predose Levels During Antibiotic Therapy in Mycophenolate Mofetil-Based Renal Transplantation. Therapeutic Drug Monitoring, 2007, 29, 122-126.	1.0	41
17	Monitoring of Inosine Monophosphate Dehydrogenase Activity as a Biomarker for Mycophenolic Acid Effect: Potential Clinical Implications. Therapeutic Drug Monitoring, 2007, 29, 141-149.	1.0	39
18	Enteric-Coated Mycophenolate Sodium Provides Higher Mycophenolic Acid Predose Levels Compared With Mycophenolate Mofetil: Implications for Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2007, 29, 381-384.	1.0	34
19	Evaluation of the Practicability of Limited Sampling Strategies for the Estimation of Mycophenolic Acid Exposure in Chinese Adult Renal Recipients. Therapeutic Drug Monitoring, 2007, 29, 600-606.	1.0	9

#	Article	IF	Citations
20	Concentrations of Mycophenolic Acid and Glucuronide Metabolites Under Concomitant Therapy With Cyclosporine or Tacrolimus. Therapeutic Drug Monitoring, 2007, 29, 87-95.	1.0	20
21	The Impact of Renal Allograft Function on Exposure and Elimination of Mycophenolic Acid (MPA) and Its Metabolite MPA 7-O-glucuronide. Transplantation, 2007, 84, 362-373.	0.5	52
22	Mycophenolate Mofetil Levels in Stable Kidney Transplant Recipients. Transplantation Proceedings, 2007, 39, 2182-2184.	0.3	4
23	Variability of Mycophenolate Mofetil Trough Levels in Stable Kidney Transplant Patients. Transplantation Proceedings, 2007, 39, 2185-2186.	0.3	7
24	Elective Conversion from CellCept to Myfortic Under Control of Mycophenolic Acid Concentration in Stable Heart Transplant Recipients. Journal of Heart and Lung Transplantation, 2007, 26, 303-304.	0.3	2
25	Safety considerations with mycophenolate sodium. Expert Opinion on Drug Safety, 2007, 6, 445-449.	1.0	19
26	Pharmacokinetics of Mycophenolic Acid and Estimation of Exposure Using Multiple Linear Regression Equations in Chinese Renal Allograft Recipients. Clinical Pharmacokinetics, 2007, 46, 389-401.	1.6	22
27	Development of a CE method for the determination of mycophenolic acid in human plasma: A comparison with HPLC. Electrophoresis, 2007, 28, 3908-3914.	1.3	8
28	Validation of limited sampling strategy for the estimation of mycophenolic acid exposure in Chinese adult liver transplant recipients. Liver Transplantation, 2007, 13, 1684-1693.	1.3	18
29	Therapeutic drug measurement of mycophenolic acid derivatives in transplant patients. Clinical Biochemistry, 2007, 40, 752-764.	0.8	35
30	Liquid chromatographic determination of mycophenolic acid and its metabolites in human kidney transplant plasma: Pharmacokinetic application. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 859, 276-281.	1.2	27
31	Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients. Clinical Transplantation, 2007, 21, 413-416.	0.8	10
32	Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. British Journal of Clinical Pharmacology, 2007, 63, 541-547.	1.1	22
33	Time-dependent clearance of mycophenolic acid in renal transplant recipients. British Journal of Clinical Pharmacology, 2007, 63, 741-752.	1.1	63
34	Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. British Journal of Clinical Pharmacology, 2007, 64, 070621084156014-???.	1.1	20
35	Lack of an Effect of Oral Iron Administration on Mycophenolic Acid Pharmacokinetics in Stable Renal Transplant Recipients. Pharmacotherapy, 2007, 27, 1272-1278.	1.2	9
36	Pharmacokinetic and Pharmacodynamic Comparison of Enteric-Coated Mycophenolate Sodium and Mycophenolate Mofetil in Maintenance Renal Transplant Patients. American Journal of Transplantation, 2007, 7, 888-898.	2.6	103
37	One-Year Results with Extended-Release Tacrolimus/MMF, Tacrolimus/MMF and Cyclosporine/MMF in De Novo Kidney Transplant Recipients. American Journal of Transplantation, 2007, 7, 595-608.	2.6	170

#	Article	IF	Citations
38	Plasma Concentrations of Mycophenolic Acid Acyl Glucuronide Are Not Associated with Diarrhea in Renal Transplant Recipients. American Journal of Transplantation, 2007, 7, 1822-1831.	2.6	65
39	Therapeutic Monitoring of Mycophenolic Acid: Is There Clinical Utility?. American Journal of Transplantation, 2007, 7, 2441-2442.	2.6	14
40	Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation. American Journal of Transplantation, 2007, 7, 2496-2503.	2.6	368
41	Pharmacogenetic effect of the UGT polymorphisms on mycophenolate is modified by calcineurin inhibitors. European Journal of Clinical Pharmacology, 2008, 64, 1047-1056.	0.8	43
42	Comparison of high-performance liquid chromatography and enzyme-multiplied immunoassay technique to monitor mycophenolic acid in paediatric renal recipients. Pediatric Nephrology, 2008, 23, 1859-1865.	0.9	23
43	Comparison of a new enzymatic assay with a high-performance liquid chromatography/ ultraviolet detection method for therapeutic drug monitoring of mycophenolic acid in adult liver transplant recipients. Liver Transplantation, 2008, 14, 1745-1751.	1.3	17
44	Simultaneous determination of mycophenolic acid and its glucuronides in human plasma using isocratic ion pair high-performance liquid chromatography. Journal of Pharmaceutical and Biomedical Analysis, 2008, 46, 603-608.	1.4	34
46	Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Bone Marrow Transplantation, 2008, 42, 113-120.	1.3	32
47	Calcineurin-inhibitor avoidance in elderly renal allograft recipients using ATG and basiliximab combined with mycophenolate mofetil. Transplant International, 2008, 21, 637-645.	0.8	18
48	Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9. British Journal of Clinical Pharmacology, 2008, 65, 893-907.	1.1	59
49	A Review of Albumin Binding in CKD. American Journal of Kidney Diseases, 2008, 51, 839-850.	2.1	99
50	Pharmacokinetic Study of Mycophenolate Mofetil in Patients with Systemic Lupus Erythematosus and Design of Bayesian Estimator Using Limited Sampling Strategies. Clinical Pharmacokinetics, 2008, 47, 277-284.	1.6	48
51	Population Pharmacokinetics of Mycophenolic Acid. Clinical Pharmacokinetics, 2008, 47, 827-838.	1.6	79
52	Handbook of Drug Monitoring Methods. , 2008, , .		13
53	Performance of Limited Sampling Strategies for Predicting Mycophenolic Acid Area Under the Curve in Thoracic Transplant Recipients. Journal of Heart and Lung Transplantation, 2008, 27, 325-328.	0.3	11
54	Stability of mycophenolic acid and glucuronide metabolites in human plasma and the impact of deproteinization methodology. Clinica Chimica Acta, 2008, 389, 87-92.	0.5	32
55	Current target ranges of mycophenolic acid exposure and drug-related adverse events: A 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clinical Therapeutics, 2008, 30, 673-683.	1.1	100
56	Models for the prediction of mycophenolic acid area under the curve using a limited-sampling strategy and an enzyme multiplied immunoassay technique in chinese patients undergoing liver transplantation. Clinical Therapeutics, 2008, 30, 2387-2401.	1.1	15

#	Article	IF	Citations
57	Higher Mycophenolate Dose Requirements in Children Undergoing Hematopoietic Cell Transplant (HCT). Journal of Clinical Pharmacology, 2008, 48, 485-494.	1.0	19
59	Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. Nephrology Dialysis Transplantation, 2008, 23, 3514-3520.	0.4	77
60	Therapeutic drug monitoring for mycophenolic acid in patients with autoimmune diseases. Nephrology Dialysis Transplantation, 2008, 23, 3386-3388.	0.4	18
62	Preliminary Experience With Renal Transplantation in HIV+ Recipients: Low Acute Rejection and Infection Rates. Transplantation, 2008, 86, 269-274.	0.5	56
63	Pharmacodynamics of Mycophenolic Acid in CD4+ Cells: A Single-Dose Study of IMPDH and Purine Nucleotide Responses in Healthy Individuals. Therapeutic Drug Monitoring, 2008, 30, 647-655.	1.0	19
64	First Clinical Experience With the New Once-Daily Formulation of Tacrolimus. Therapeutic Drug Monitoring, 2008, 30, 159-166.	1.0	53
65	Impact of Changing From Cyclosporine to Tacrolimus on Pharmacokinetics of Mycophenolic acid in Renal Transplant Recipients With Diabetes. Therapeutic Drug Monitoring, 2008, 30, 591-596.	1.0	13
66	Long-Term Pharmacokinetics of Mycophenolic Acid in Pediatric Renal Transplant Recipients Over 3 Years Posttransplant. Therapeutic Drug Monitoring, 2008, 30, 570-575.	1.0	33
67	Individualization of immunosuppression: concepts and rationale. Current Opinion in Organ Transplantation, 2008, 13, 604-608.	0.8	36
68	Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial. Transplantation, 2008, 86, 1043-1051.	0.5	238
69	Immunosuppression in Pediatric Kidney Transplantation. , 2008, , 905-929.		5
70	Defining Algorithms for Efficient Therapeutic Drug Monitoring of Mycophenolate Mofetil in Heart Transplant Recipients. Therapeutic Drug Monitoring, 2008, 30, 419-427.	1.0	26
71	Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection. Therapeutics and Clinical Risk Management, 2009, 5, 139.	0.9	17
72	Clinical utility of therapeutic drug monitoring of mycophenolic acid in transplantation medicine: Where are we? / Der klinische Nutzen des Therapeutischen Drug Monitoring von MycophenolsÃure in der Transplantationsmedizin: Wo stehen wir?. Laboratoriums Medizin, 2009, 33, 88-98.	0.1	1
73	Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study. Lupus, 2009, 18, 441-447.	0.8	36
74	Fixed- or Controlled-Dose Mycophenolate Mofetil with Standard- or Reduced-Dose Calcineurin Inhibitors: The Opticept Trial. American Journal of Transplantation, 2009, 9, 1607-1619.	2.6	160
75	Proton Pump Inhibitors Reduce Mycophenolate Exposure in Heart Transplant Recipients-A Prospective Case-Controlled Study. American Journal of Transplantation, 2009, 9, 1650-1656.	2.6	49
77	Enhanced detection in capillary electrophoresis: Example determination of serum mycophenolic acid. Electrophoresis, 2009, 30, 1516-1521.	1.3	10

#	Article	IF	Citations
78	Comparison of pharmacokinetics of mycophenolic acid and its metabolites between living donor liver transplant recipients and deceased donor liver transplant recipients. Liver Transplantation, 2009, 15, 1473-1480.	1.3	6
79	Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. Journal of Pharmacokinetics and Pharmacodynamics, 2009, 36, 541-564.	0.8	73
80	Two sampling time profiles for the abbreviated estimation of mycophenolic acid area under the curve in adult renal transplant recipients treated with mycophenolate mofetil and concomitant tacrolimus. Journal of Clinical Pharmacy and Therapeutics, 2009, 34, 531-537.	0.7	2
81	Increased Mycophenolic Acid Exposure in Stable Kidney Transplant Recipients on Tacrolimus as Compared With Those on Sirolimus: Implications for Pharmacokinetics. Clinical Pharmacology and Therapeutics, 2009, 86, 411-415.	2.3	20
82	Population Pharmacokinetics and Pharmacogenetics of Tacrolimus in De Novo Pediatric Kidney Transplant Recipients. Clinical Pharmacology and Therapeutics, 2009, 86, 609-618.	2.3	142
83	UGT Genotype May Contribute to Adverse Events Following Medication With Mycophenolate Mofetil in Pediatric Kidney Transplant Recipients. Clinical Pharmacology and Therapeutics, 2009, 85, 495-500.	2.3	38
84	Combination of CsA, MTX and low-dose, short-course mycophenolate mofetil for GVHD prophylaxis. Bone Marrow Transplantation, 2009, 43, 61-67.	1.3	19
85	Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation. Bone Marrow Transplantation, 2009, 44, 113-120.	1.3	26
86	Analysis of mycophenolic acid in dried blood spots using reversed phase high performance liquid chromatography. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 3916-3919.	1.2	30
87	Pharmacokinetics of Mycophenolic Acid Administered 3 Times Daily after Hematopoietic Stem Cell Transplantation with Reduced-Intensity Regimen. Biology of Blood and Marrow Transplantation, 2009, 15, 1134-1139.	2.0	15
88	Graft Outcome and Mycophenolic Acid Trough Level Monitoring in Kidney Transplantation. Transplantation Proceedings, 2009, 41, 2102-2103.	0.3	4
89	The Prevalence of Uridine Diphosphate-Glucuronosyltransferase 1A9 (UGT1A9) Gene Promoter Region Single-Nucleotide Polymorphisms T-275A and C-2152T and Its Influence on Mycophenolic Acid Pharmacokinetics in Stable Renal Transplant Patients. Transplantation Proceedings, 2009, 41, 2313-2316.	0.3	38
90	Mycophenolate Mofetil Absorption Quotient: Interest to Clinical Practice. Transplantation Proceedings, 2009, 41, 2317-2319.	0.3	2
91	Validation of Limited Sampling Strategy for Estimation of Mycophenolic Acid Exposure During the First Year After Heart Transplantation. Transplantation Proceedings, 2009, 41, 4277-4284.	0.3	11
92	Proton Pump Inhibitor Co-medication Reduces Mycophenolate Acid Drug Exposure in Heart Transplant Recipients. Journal of Heart and Lung Transplantation, 2009, 28, 605-611.	0.3	52
93	Mycophenolic Acid Exposure after Administration of Mycophenolate Mofetil in the Presence and Absence of Ciclosporin in Renal Transplant Recipients. Clinical Pharmacokinetics, 2009, 48, 329-341.	1.6	40
94	Pharmacokinetic Modelling and Development of Bayesian Estimators for Therapeutic Drug Monitoring of Mycophenolate Mofetil in Reduced-Intensity Haematopoietic Stem Cell Transplantation. Clinical Pharmacokinetics, 2009, 48, 667-675.	1.6	30
95	Pharmacokinetic Optimization of Immunosuppressive Therapy in Thoracic Transplantation: Part I. Clinical Pharmacokinetics, 2009, 48, 419-462.	1.6	55

#	Article	IF	Citations
96	Pharmacokinetic Optimization of Immunosuppressive Therapy in Thoracic Transplantation: Part II. Clinical Pharmacokinetics, 2009, 48, 489-516.	1.6	38
97	Treatment Strategies to Minimize or Prevent Chronic Allograft Dysfunction in Pediatric Renal Transplant Recipients. Paediatric Drugs, 2009, 11, 381-396.	1.3	31
98	A Fast Ultra-Performance Liquid Chromatography Method for Simultaneous Quantification of Mycophenolic Acid and Its Phenol- and Acyl-Glucuronides in Human Plasma. Therapeutic Drug Monitoring, 2009, 31, 110-115.	1.0	24
99	Differential Proteomic Analysis of Lymphocytes Treated With Mycophenolic Acid Reveals Caspase 3-Induced Cleavage of Rho GDP Dissociation Inhibitor 2. Therapeutic Drug Monitoring, 2009, 31, 211-217.	1.0	12
100	Clinical Utility of a New Enzymatic Assay for Determination of Mycophenolic Acid in Comparison With an Optimized LC-MS/MS Method. Therapeutic Drug Monitoring, 2009, 31, 218-223.	1.0	19
101	Comparison of 3 Estimation Methods of Mycophenolic Acid AUC based on a Limited Sampling Strategy in Renal Transplant Patients. Therapeutic Drug Monitoring, 2009, 31, 224-232.	1.0	11
102	The Challenge of Achieving Target Drug Concentrations in Clinical Trials: Experience From the Symphony Study. Transplantation, 2009, 87, 1360-1366.	0.5	55
103	Pharmacokinetics of Mycophenolic Acid and Its Glucuronide Metabolites in Stable Adult Liver Transplant Recipients With Renal Dysfunction on a Low-Dose Calcineurin Inhibitor Regimen and Mycophenolate Mofetil. Therapeutic Drug Monitoring, 2009, 31, 205-210.	1.0	13
104	Limited Sampling Strategies for Therapeutic Drug Monitoring of Mycophenolate Mofetil Therapy in Patients With Autoimmune Disease. Therapeutic Drug Monitoring, 2009, 31, 382-390.	1.0	31
105	New Insights Into the Pharmacokinetics and Pharmacodynamics of the Calcineurin Inhibitors and Mycophenolic Acid: Possible Consequences for Therapeutic Drug Monitoring in Solid Organ Transplantation. Therapeutic Drug Monitoring, 2009, 31, 416-435.	1.0	146
106	Mycophenolic Acid 12-Hour Area Under the Curve in De Novo Liver Transplant Patients Given Mycophenolate Mofetil at Fixed Versus Concentration-Controlled Doses. Therapeutic Drug Monitoring, 2009, 31, 451-456.	1.0	7
107	Performance of the New Mycophenolate Assay Based on IMPDH Enzymatic Activity for Pharmacokinetic Investigations and Setup of Bayesian Estimators in Different Populations of Allograft Recipients. Therapeutic Drug Monitoring, 2009, 31, 443-450.	1.0	11
108	Therapeutic Monitoring of Mycophenolate in Transplantation: Is It Justified?. Current Drug Metabolism, 2009, 10, 179-187.	0.7	32
109	Limited Sampling Strategies Drawn Within 3 Hours Postdose Poorly Predict Mycophenolic Acid Area-Under-the-Curve After Enteric-Coated Mycophenolate Sodium. Therapeutic Drug Monitoring, 2009, 31, 585-591.	1.0	27
110	Investigation of the Crossreactivity of Mycophenolic Acid Glucuronide Metabolites and of Mycophenolate Mofetil in the Cedia MPA Assay. Therapeutic Drug Monitoring, 2010, 32, 79-85.	1.0	27
111	Evaluation of the Mycophenolic Acid Exposure Estimation Methods Used in the APOMYGERE, FDCC, and Opticept Trials. Transplantation, 2010, 90, 44-51.	0.5	21
112	Biomarkers as a Tool for Management of Immunosuppression in Transplant Patients. Therapeutic Drug Monitoring, 2010, 32, 560-572.	1.0	54
113	Target Enzyme Activity as a Biomarker for Immunosuppression. Therapeutic Drug Monitoring, 2010, 32, 257-260.	1.0	6

#	Article	IF	Citations
114	Evaluation of Limited Sampling Strategies for Mycophenolic Acid After Mycophenolate Mofetil Intake in Adult Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2010, 32, 723-733.	1.0	26
115	Cost-Effectiveness Analysis of Individualized Mycophenolate Mofetil Dosing in Kidney Transplant Patients in the APOMYGRE Trial. Transplantation, 2010, 89, 1255-1262.	0.5	15
116	Renal Transplant Patients at High Risk of Acute Rejection Benefit From Adequate Exposure to Mycophenolic Acid. Transplantation, 2010, 89, 595-599.	0.5	48
117	A Reliable Limited Sampling Strategy for the Estimation of Mycophenolic Acid Area Under the Concentration Time Curve in Adult Renal Transplant Patients in the Stable Posttransplant Period. Therapeutic Drug Monitoring, 2010, 32, 136-140.	1.0	19
118	Use of two validated in vitro tests to assess the embryotoxic potential of mycophenolic acid. Archives of Toxicology, 2010, 84, 37-43.	1.9	23
119	Pharmacogenetic Impact of UDP-Glucuronosyltransferase Metabolic Pathway and Multidrug Resistanceâ€“Associated Protein 2 Transport Pathway on Mycophenolic Acid in Thoracic Transplant Recipients: An Exploratory Study. Pharmacotherapy, 2010, 30, 1097-1108.	1.2	21
120	Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Arthritis and Rheumatism, 2010, 62, 2047-2054.	6.7	85
121	A therapeutic exploratory study to determine the efficacy and safety of calcineurin-inhibitor-free de-novo immunosuppression after liver transplantation: CILT. BMC Surgery, 2010, 10, 15.	0.6	11
122	Correlation of IMPDH1 Gene Polymorphisms with Subclinical Acute Rejection and Mycophenolic Acid Exposure Parameters on Day 28 after Renal Transplantation. Basic and Clinical Pharmacology and Toxicology, 2010, 107, 631-636.	1.2	34
123	Inosine monophosphate dehydrogenase variability in renal transplant patients on longâ€term mycophenolate mofetil therapy. British Journal of Clinical Pharmacology, 2010, 69, 38-50.	1.1	39
124	Pharmacokinetic and pharmacodynamic analysis of entericâ€coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. British Journal of Clinical Pharmacology, 2010, 69, 346-357.	1.1	57
125	Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. British Journal of Clinical Pharmacology, 2010, 69, 358-366.	1.1	34
126	Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. British Journal of Clinical Pharmacology, 2010, 70, 567-579.	1.1	25
127	Randomized crossover study to assess the interâ€and intrasubject variability of morning mycophenolic acid concentrations from entericâ€coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients. Clinical Transplantation, 2010, 24, E116-23.	0.8	11
128	Consensus Report on Therapeutic Drug Monitoring of Mycophenolic Acid in Solid Organ Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 341-358.	2.2	276
129	Immunsuppressiva-Medikamentenspiegelmessung â€“ reine Routine? / Immunosuppressant drug monitoring: a routine undertaking?. Laboratoriums Medizin, 2010, 34, 117-128.	0.1	1
130	Immunosuppressant drug monitoring â€“ a routine undertaking? 1. Laboratoriums Medizin, 2010, 34, -.	0.1	0
131	State of the art in therapeutic drug monitoring. Clinical Chemistry and Laboratory Medicine, 2010, 48, 437-446.	1.4	16

#	Article	IF	Citations
132	Population Pharmacokinetics and Pharmacogenetics of Mycophenolic Acid Following Administration of Mycophenolate Mofetil in De Novo Pediatric Renalâ€Transplant Patients. Journal of Clinical Pharmacology, 2010, 50, 1280-1291.	1.0	61
133	SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics, 2010, 11, 1703-1713.	0.6	48
134	Pharmacokinetics and Pharmacodynamics of Intensified versus Standard Dosing of Mycophenolate Sodium in Renal Transplant Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 503-511.	2.2	40
135	Pharmacogenetic influences on mycophenolate therapy. Pharmacogenomics, 2010, 11, 369-390.	0.6	47
136	Can mycophenolic acid dose requirement during the first transplant help predict dosing for the second transplant?. Nephrology Dialysis Transplantation, 2010, 25, 3449-3452.	0.4	2
137	Toxicity and Monitoring of Immunosuppressive Therapy Used in Systemic Autoimmune Diseases. Clinics in Chest Medicine, 2010, 31, 565-588.	0.8	31
138	Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: Pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients. Pharmacological Research, 2010, 61, 167-174.	3.1	13
139	Mycophenolate Pharmacokinetics and Association with Response to Acute Graft-versus-Host Disease Treatment from the Blood and Marrow Transplant Clinical Trials Network. Biology of Blood and Marrow Transplantation, 2010, 16, 421-429.	2.0	32
140	LCâ€“MS/MS for immunosuppressant therapeutic drug monitoring. Bioanalysis, 2010, 2, 1141-1153.	0.6	21
141	Development of a Bayesian estimator for the therapeutic drug monitoring of mycophenolate mofetil in children with idiopathic nephrotic syndrome. Pharmacological Research, 2011, 63, 423-431.	3.1	44
142	The Evolution of Population Pharmacokinetic Models to Describe the Enterohepatic Recycling of Mycophenolic Acid in Solid Organ Transplantation and Autoimmune Disease. Clinical Pharmacokinetics, 2011, 50, 1-24.	1.6	50
143	UPLC MS/MS method for quantification of mycophenolic acid and metabolites in human plasma: Application to pharmacokinetic study. Clinica Chimica Acta, 2011, 412, 59-65.	0.5	34
145	Clinical Pharmacokinetics of Triple Immunosuppression Scheme in Kidney Transplant (Tacrolimus,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50		2
146	Safety and Efficacy of Intensified Versus Standard Dosing Regimens of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Patients. Transplantation, 2011, 91, 779-785.	0.5	26
147	Therapeutic Drug Monitoring of Mycophenolic Acid After Lung Transplantationâ€"Is It Clinically Relevant?. Transplantation, 2011, 91, e33-e34.	0.5	2
148	Large Scale Analysis of Routine Dose Adjustments of Mycophenolate Mofetil Based on Global Exposure in Renal Transplant Patients. Therapeutic Drug Monitoring, 2011, 33, 285-294.	1.0	44
149	Early Steroid Withdrawal and Optimization of Mycophenolic Acid Exposure in Kidney Transplant Recipients Receiving Mycophenolate Mofetil. Transplantation, 2011, 92, 1244-1251.	0.5	24
150	Monitoring of Mycophenolic Acid Predose Concentrations in the Maintenance Phase More Than One Year After Renal Transplantation. Therapeutic Drug Monitoring, 2011, 33, 295-302.	1.0	15

#	Article	IF	Citations
151	Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure. Transplantation Reviews, 2011, 25, 47-57.	1.2	116
152	Pediatric aspects of therapeutic drug monitoring of mycophenolic acid in renal transplantation. Transplantation Reviews, 2011, 25, 78-89.	1.2	66
153	Therapeutic drug monitoring of mycophenolates in kidney transplantation: report of The Transplantation Society consensus meeting. Transplantation Reviews, 2011, 25, 58-64.	1.2	65
154	Pharmacokinetics-based optimal dose prediction of donor source-dependent response to mycophenolate mofetil in unrelated hematopoietic cell transplantation. International Journal of Hematology, 2011, 94, 193-202.	0.7	22
155	A limited sampling strategy for estimation of the area under the curve (0 to 8 hours) of mycophenolic acid administered three times daily to liver transplant recipients. Upsala Journal of Medical Sciences, 2011, 116, 47-51.	0.4	2
156	Immunosuppressive and Cytotoxic Therapy: Pharmacology, Toxicities, and Monitoring. Seminars in Respiratory and Critical Care Medicine, 2011, 32, 346-370.	0.8	11
157	Limited Sampling Strategy for Estimating Individual Exposure of Tacrolimus in Pediatric Kidney Transplant Patients. Therapeutic Drug Monitoring, 2011, 33, 681-687.	1.0	23
158	Performance of the Roche Total Mycophenolic AcidÂ® assay on the Cobas Integra 400Â®, Cobas 6000Â® and comparison to LC-MS/MS in liver transplant patients. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1159-65.	1.4	15
159	UGT1A9, UGT2B7, and MRP2 Genotypes Can Predict Mycophenolic Acid Pharmacokinetic Variability in Pediatric Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2012, 34, 671-679.	1.0	48
160	Immunosuppressive Drug Monitoring. , 2012, , 323-348.		2
161	Therapeutic Monitoring of Immunotherapies in Autoimmune Diseases. Current Pharmaceutical Design, 2012, 18, 4550-4555.	0.9	5
162	Randomized Trial Comparing Late Concentration-Controlled Calcineurin Inhibitor or Mycophenolate Mofetil Withdrawal. Transplantation, 2012, 93, 887-894.	0.5	32
163	Pharmacokinetics of free mycophenolic acid and limited sampling strategy for the estimation of area under the curve in liver transplant patients. European Journal of Pharmaceutical Sciences, 2012, 47, 636-641.	1.9	10
164	Current trends in immunosuppressive therapies for renal transplant recipients. American Journal of Health-System Pharmacy, 2012, 69, 1961-1975.	0.5	51
165	New-Onset Diabetes After Renal Transplantation. Diabetes Care, 2012, 35, 181-188.	4.3	105
166	Inosine 5â€²-monophosphate dehydrogenase activity as a biomarker in the field of transplantation. Clinica Chimica Acta, 2012, 413, 1391-1397.	0.5	25
167	Monitoring of Nonsteroidal Immunosuppressive Drugs in Patients With Lung Disease and Lung Transplant Recipients. Chest, 2012, 142, e1S-e111S.	0.4	52
168	Significance of Mycophenolate Monitoring in Liver Transplant Recipients: Toward the Cut-off Level. Transplantation Proceedings, 2012, 44, 2157-2161.	0.3	6

#	Article	IF	Citations
171	Immunosuppressive Therapy for Autoimmune Lung Diseases. Immunology and Allergy Clinics of North America, 2012, 32, 633-669.	0.7	12
172	Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase. Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 217-220.	0.7	11
173	Pharmacokinetics and pharmacodynamics of mycophenolate sodium (ECâ€MPS) coâ€administered with cyclosporine in the earlyâ€phase postâ€kidney transplantation. Clinical Transplantation, 2012, 26, 57-66.	0.8	14
174	Polymorphisms of UGT1A9 and UGT2B7 influence the pharmacokinetics of mycophenolic acid after a single oral dose in healthy Chinese volunteers. European Journal of Clinical Pharmacology, 2013, 69, 843-849.	0.8	31
175	Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Patients with Autoimmune Disease. Clinical Pharmacokinetics, 2013, 52, 303-331.	1.6	65
176	Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil. Lupus, 2013, 22, 171-179.	0.8	28
177	Clinical evaluation of a dried blood spot method for determination of mycophenolic acid in renal transplant patients. Clinical Biochemistry, 2013, 46, 1905-1908.	0.8	30
178	Genes and beans: pharmacogenomics of renal transplant. Pharmacogenomics, 2013, 14, 769-781.	0.6	15
179	Therapeutic dose monitoring of mycophenolate mofetil in dermatologic diseases. Journal of the American Academy of Dermatology, 2013, 68, 36-40.	0.6	14
180	Controlled-Dose Versus Fixed-Dose Mycophenolate Mofetil for Kidney Transplant Recipients. Transplantation, 2013, 96, 361-367.	0.5	19
181	A Protocol for the Pharmacokinetics of Enteric Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN): an open-label, randomised controlled trial. BMJ Open, 2013, 3, e003511.	0.8	2
182	Combined approach with therapeutic drug monitoring and pharmacogenomics in renal transplant recipients. Indian Journal of Nephrology, 2013, 23, 71.	0.2	2
183	Evaluation of Mycophenolic Acid Exposure Using a Limited Sampling Strategy in Renal Transplant Recipients. American Journal of Nephrology, 2013, 37, 534-540.	1.4	12
184	Longâ€term outcomes after cyclosporine or mycophenolate withdrawal in kidney transplantation â€“ results from an aborted trial. Clinical Transplantation, 2013, 27, E151-6.	0.8	13
185	Limited Sampling Strategy for the Estimation of Mycophenolic Acid Area under the Concentrationâ€“Time Curve Treated in Japanese Living-Related Renal Transplant Recipients with Concomitant Extended-Release Tacrolimus. Biological and Pharmaceutical Bulletin, 2013, 36, 1036-1039.	0.6	12
186	Monitoring of Inosine Monophosphate Dehydrogenase Activity and Expression during the Early Period of Mycophenolate Mofetil Therapy in De Novo Renal Transplant Patients. Drug Metabolism and Pharmacokinetics, 2013, 28, 109-117.	1.1	14
187	Contemporary management of pemphigus. Expert Opinion on Orphan Drugs, 2013, 1, 295-314.	0.5	6
188	Modulation of Candida albicans Virulence by Antirejection Immunosuppressant Drugs. Transplantation, 2013, 95, e16-e18.	0.5	0

#	Article	IF	Citations
189	Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. Annals of Transplantation, 2013, 18, 43-52.	0.5	7
190	Clinical Pharmacology and Therapeutic Drug Monitoring of Immunosuppressive Agents. , 2013, , .		1
191	Limited Sampling Model for Advanced Mycophenolic Acid Therapeutic Drug Monitoring After Liver Transplantation. Therapeutic Drug Monitoring, 2014, 36, 141-147.	1.0	19
192	Similar MPA Exposure on Modified Release and Regular Tacrolimus. Therapeutic Drug Monitoring, 2014, 36, 353-357.	1.0	7
193	Unusually late-onset mycophenolate mofetilâ€“related colitis. American Journal of Health-System Pharmacy, 2014, 71, 1858-1861.	0.5	10
194	Determination of mycophenolic acid in human plasma by ultra performance liquid chromatography tandem mass spectrometry. Journal of Pharmaceutical Analysis, 2014, 4, 205-216.	2.4	14
195	How Accurate and Precise Are Limited Sampling Strategies in Estimating Exposure to Mycophenolic Acid in People with Autoimmune Disease?. Clinical Pharmacokinetics, 2014, 53, 227-245.	1.6	14
196	Mycophenolate mofetil in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a prospective pharmacokinetics and clinical study. Clinical and Experimental Immunology, 2014, 176, 172-179.	1.1	10
197	Successful treatment of <scp>BK</scp> virus nephropathy using therapeutic drug monitoring of mycophenolic acid. Nephrology, 2014, 19, 37-41.	0.7	4
198	Shortâ€term therapeutic drug monitoring of mycophenolic acid reduces infection: a prospective, singleâ€center cohort study in Chinese livingâ€related kidney transplantation. Transplant Infectious Disease, 2014, 16, 760-766.	0.7	6
199	Acute mycophenolate overdose: case series and systematic literature analysis. Expert Opinion on Drug Safety, 2014, 13, 525-534.	1.0	10
200	Validation of an LCâ€“MS/MS method for the quantification of mycophenolic acid in human kidney transplant biopsies. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 945-946, 171-177.	1.2	18
201	The effect of MMF dose and trough levels on adverse effects in pediatric heart transplant recipients. Pediatric Transplantation, 2015, 19, 618-622.	0.5	8
202	What is the intrapatient variability of mycophenolic acid trough levels?. Pediatric Transplantation, 2015, 19, 669-674.	0.5	19
203	A Comparison of the Immunochemical Methods, PETINIA and EMIT, With That of HPLC-UV for the Routine Monitoring of Mycophenolic Acid in Heart Transplant Patients. Therapeutic Drug Monitoring, 2015, 37, 311-318.	1.0	22
204	Clinically-relevant cyclosporin and rapamycin concentrations enhance regulatory T cell function to a similar extent but with different mechanisms: An in-vitro study in healthy humans. International Immunopharmacology, 2015, 24, 276-284.	1.7	15
205	Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients. Pharmacological Research, 2015, 99, 308-315.	3.1	22
206	The evaluation of enteric-coated mycophenolate sodium in cardiac deceased donor liver transplant patients in China. Immunopharmacology and Immunotoxicology, 2015, 37, 508-512.	1.1	3

#	Article	IF	Citations
207	Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring. Clinical Rheumatology, 2015, 34, 171-174.	1.0	22
208	A comprehensive review of the published assays for the quantitation of the immunosuppressant drug mycophenolic acid and its glucuronidated metabolites in biological fluids. Biomedical Chromatography, 2016, 30, 721-748.	0.8	15
209	Pharmacokinetics and target attainment of mycophenolate in pediatric renal transplant patients. Pediatric Transplantation, 2016, 20, 492-499.	0.5	14
210	Therapeutic Drug Monitoring of Everolimus. Therapeutic Drug Monitoring, 2016, 38, 143-169.	1.0	102
211	Therapeutic Drug Monitoring of Mycophenolic Acid. Advances in Clinical Chemistry, 2016, 76, 165-184.	1.8	21
212	Pharmacokinetics of mycophenolate sodium co-administered with tacrolimus in the first year after renal transplantation. European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41, 331-338.	0.6	8
213	Application of liquid chromatography combined with mass spectrometry or tandem mass spectrometry for therapeutic drug monitoring of immunosuppressants. , 2016, , 57-81.		5
214	Graft-derived cell-free DNA as a marker of graft integrity after transplantation. , 2016, , 153-176.		2
215	Usefulness of mycophenolic acid monitoring with PETINIA for prediction of adverse events in kidney transplant recipients. Scandinavian Journal of Clinical and Laboratory Investigation, 2016, 76, 296-303.	0.6	7
216	Overview of the pharmacology and toxicology of immunosuppressant agents that require therapeutic drug monitoring. , 2016, , 1-27.		2
217	Metabolic syndrome and new onset diabetes after kidney transplantation. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2017, 11, 211-214.	1.8	3
218	Immunology of Liver Transplantation. , 2017, , 333-353.		0
219	Renal Transplant Acute Rejection with Lower Mycophenolate Mofetil Dosing and Proton Pump Inhibitors or Histamineâ€2 Receptor Antagonists. Pharmacotherapy, 2017, 37, 1507-1515.	1.2	7
220	Estimation of Mycophenolic Acid Area Under the Curve With Limited-Sampling Strategy in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium. Therapeutic Drug Monitoring, 2017, 39, 29-36.	1.0	16
221	Clinical Pharmacokinetics of Mycophenolic Acid in Hematopoietic Stem Cell Transplantation Recipients. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 183-189.	0.6	22
222	The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients. British Journal of Clinical Pharmacology, 2017, 83, 812-822.	1.1	30
223	Evaluation of Mycophenolate Mofetil and Low-Dose Steroid Combined Therapy in Moderately Severe Henoch-SchÃ¶nlein Purpura Nephritis. Medical Science Monitor, 2017, 23, 2333-2339.	0.5	10
224	Determination of Mycophenolic Acid and Mycophenolic Acid Glucuronide Using Liquid Chromatography Tandem Mass Spectrometry (LC/MS/MS). Current Protocols in Toxicology / Editorial Board, Mahin D Maines (editor-in-chief) [et Al], 2018, 75, 18.21.1-18.21.8.	1.1	3

#	Article	IF	Citations
225	Randomized openâ€label crossover assessment of Prograf vs Advagraf on immunosuppressant pharmacokinetics and pharmacodynamics in simultaneous pancreasâ€kidney patients. Clinical Transplantation, 2018, 32, e13180.	0.8	9
226	Monitoring of Mycophenolic Acid Trough Concentration in Kidney Transplant under Cyclosporine Is Beneficial in Reducing Acute Rejection within 1 Year. The Journal of the Korean Society for Transplantation, 2018, 32, 75.	0.2	0
227	Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Exposure in Chinese Renal Allograft Recipients After Administration of ECâ€MPS. Journal of Clinical Pharmacology, 2019, 59, 578-589.	1.0	13
228	Review of approaches and examples for monitoring biotransformation in protein and peptide therapeutics by MS. Bioanalysis, 2018, 10, 1877-1890.	0.6	18
229	Replacement of mycophenolate mofetil with a JAK inhibitor, AS2553627, in combination with low-dose tacrolimus, for renal allograft rejection in non-human primates. International Immunopharmacology, 2018, 64, 201-207.	1.7	4
230	Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus. Therapeutic Drug Monitoring, 2018, 40, 572-580.	1.0	4
231	Mycophenolic acid concentrations in peripheral blood mononuclear cells are associated with the incidence of rejection in renal transplant recipients. British Journal of Clinical Pharmacology, 2018, 84, 2433-2442.	1.1	15
232	Efficacy, Tolerance, and Plasma Levels of Abiraterone and Its Main Metabolites in a Patient With Metastatic Castration-resistant Prostate Cancer With a Hepatic Transplant. Clinical Genitourinary Cancer, 2019, 17, e893-e896.	0.9	0
233	The development of a population physiologically based pharmacokinetic model for mycophenolic mofetil and mycophenolic acid in humans using data from plasma, saliva, and kidney tissue. Biopharmaceutics and Drug Disposition, 2019, 40, 325-340.	1.1	13
234	Low incidence of acute rejection within 6 months of kidney transplantation in HIVâ€infected recipients treated with raltegravir: the Agence Nationale de Recherche sur le Sida et les HÃ©patites Virales (ANRS) 153 TREVE trial. HIV Medicine, 2019, 20, 202-213.	1.0	7
235	Macrophage lipid accumulation in the presence of immunosuppressive drugs mycophenolate mofetil and cyclosporin A. Inflammation Research, 2019, 68, 787-799.	1.6	9
236	Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients. International Journal of Clinical Pharmacy, 2019, 41, 1047-1055.	1.0	3
237	Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Postâ€“Renal Transplant. Journal of Clinical Pharmacology, 2019, 59, 1351-1365.	1.0	9
238	Therapeutic Drug Monitoring of Micophenolate Mofetil in Cardiac Transplant Patients by Limited Sampling Strategy: An Update. , 2019, , .		3
239	Immunosuppressants in Organ Transplantation. Handbook of Experimental Pharmacology, 2019, 261, 441-469.	0.9	31
240	Longitudinal Pharmacokinetics of Mycophenolic Acid in Elderly Renal Transplant Recipients Compared to a Younger Control Group: Data from the nEverOld Trial. European Journal of Drug Metabolism and Pharmacokinetics, 2019, 44, 189-199.	0.6	9
241	The utility of trough mycophenolic acid levels for the management of lupus nephritis. Nephrology Dialysis Transplantation, 2019, 34, 83-89.	0.4	19
242	Mycophenolic Acid and Its Pharmacokinetic Drugâ€Drug Interactions in Humans: Review of the Evidence and Clinical Implications. Journal of Clinical Pharmacology, 2020, 60, 295-311.	1.0	19

#	Article	IF	Citations
243	Mycophenolates: The latest modern and potent immunosuppressive drugs in adult kidney transplantation: What we should know about them?. Artificial Organs, 2020, 44, 561-576.	1.0	10
244	Mycophenolate mofetil for systemic sclerosis: drug exposure exhibits considerable inter-individual variationâ€"a prospective, observational study. Arthritis Research and Therapy, 2020, 22, 230.	1.6	7
245	A new model to determine Optimal Exposure to Tacrolimus and Mycophenolate Mofetil after renal transplantation. Clinical Transplantation, 2020, 34, e13893.	0.8	4
247	A short overview on mycophenolic acid pharmacology and pharmacokinetics. Clinical Transplantation, 2020, 34, e13997.	0.8	25
248	Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis. Lupus, 2020, 29, 1067-1077.	0.8	8
249	Effect of the proton-pumpÂInhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial. Nephrology Dialysis Transplantation, 2020, 35, 1060-1070.	0.4	8
250	Immunosuppressive therapy post-transplantation in children: what the clinician needs to know. Expert Review of Clinical Immunology, 2020, 16, 139-154.	1.3	12
251	Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients. Frontiers in Pharmacology, 2020, 11, 340.	1.6	11
252	Mycophenolic acid drug monitoring in patients with systemic sclerosis associated with diffuse skin and/or pulmonary involvement: A monocentric and retrospective French study. Journal of Scleroderma and Related Disorders, 2021, 6, 87-95.	1.0	1
253	Pharmacokinetics of Enteric-Coated Mycophenolate Sodium Metabolites in Patients Over 60 Years Old Within the First Year After Renal Transplantation. Transplantation Proceedings, 2021, 53, 1001-1004.	0.3	2
254	Quantification of mycophenolic acid in human plasma by liquid chromatography with timeâ€ofâ€flight mass spectrometry for therapeutic drug monitoring. Biomedical Chromatography, 2021, 35, e5011.	0.8	2
255	Therapeutic drug monitoring. , 2021, , 243-262.		4
256	Towards therapeutic drug monitoring of mycophenolic acid in mucous membrane pemphigoid: A retrospective singleâ€centre study. Fundamental and Clinical Pharmacology, 2021, 35, 1179-1187.	1.0	3
257	Association of ABCC2 Haplotypes to Mycophenolic Acid Pharmacokinetics in Stable Kidney Transplant Recipients. Journal of Clinical Pharmacology, 2021, 61, 1592-1605.	1.0	3
258	Effect of mycophenolic acid and tacrolimus on the incidence of infectious complications after kidney transplantation. International Immunopharmacology, 2021, 98, 107908.	1.7	1
259	Immunosuppressive Drugs. , 2008, , 165-199.		4
260	Treatment of Acute Graft-vs-Host Disease. , 2010, , 747-765.		2
261	Immunosuppression in Pediatric Kidney Transplantation. , 2016, , 1767-1802.		5

#	Article	IF	Citations
262	Therapeutic Drugs and Their Management. , 2012, , 1057-1108.		3
263	Multicenter Evaluation of a New Inosine Monophosphate Dehydrogenase Inhibition Assay for Quantification of Total Mycophenolic Acid in Plasma. Therapeutic Drug Monitoring, 2008, 30, 428-433.	1.0	29
264	A Possible Simplification for the Estimation of Area Under the Curve (AUC0â€“12) of Enteric-Coated Mycophenolate Sodium in Renal Transplant Patients Receiving Tacrolimus. Therapeutic Drug Monitoring, 2011, 33, 165-170.	1.0	15
265	Clinical Implication of Mycophenolic Acid Trough Concentration Monitoring in Kidney Transplant Patients on a Tacrolimus Triple Maintenance Regimen: A Single-Center Experience. Annals of Transplantation, 2017, 22, 707-718.	0.5	7
266	Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation. Clinical and Molecular Hepatology, 2014, 20, 291.	4.5	11
267	PK/PD Study of Mycophenolate Mofetil in Children With Systemic Lupus Erythematosus to Inform Model-Based Precision Dosing. Frontiers in Pharmacology, 2020, 11, 605060.	1.6	7
268	Generics in transplantation medicine: Randomized comparison of innovator andÂsubstitution products containing mycophenolate mofetil. International Journal of Clinical Pharmacology and Therapeutics, 2019, 57, 506-519.	0.3	7
269	Mycophenolate Mofetil-related Pancolitis in a Kidney Transplant Recipient. Experimental and Clinical Transplantation, 2012, 10, 501-505.	0.2	6
270	Herz- und Herz-Lungen-Transplantation. , 2010, , 831-846.		0
272	Clinical Pharmacologic Principles and Immunosuppression. , 2011, , 87-109.		0
273	Mycophenolic acid agents: is enteric coating the answer?. Transplant Research and Risk Management, 0, , 45.	0.7	0
274	Kapitel E1 Literaturverzeichnis zu Peter, Pichler, MÃ¼ller-Ladner (Hrsg.): Klinische Immunologie. , 2012, , e1-e80.		0
275	Immunology of Liver Transplantation. , 2015, , 1-22.		0
276	Immunology of Liver Transplantation. , 2016, , 1-22.		0
277	Induction and Maintenance Agents. Organ and Tissue Transplantation, 2019, , 1-11.	0.0	0
278	The scientific and practical substantiation of the therapeutic drug monitoring procedure: validation of the analytical method of valproic acid measurement. Clinical Pharmacy, 2019, 23, 19-26.	0.2	0
279	Induction and Maintenance Agents. Organ and Tissue Transplantation, 2020, , 193-203.	0.0	0
280	Lack of concordance between EMIT assay and LC-MS/MS for Therapeutic Drug Monitoring of Mycophenolic Acid: Potential increased risk for graft rejection?. Journal of Pharmaceutical and Biomedical Analysis, 2020, 187, 113337.	1.4	3

#	Article	IF	Citations
281	Pharmacokinetics of mycophenolic acid after haplo-hematopoietic stem cell transplantation in Japanese recipients. Journal of Oncology Pharmacy Practice, 2022, 28, 31-38.	0.5	1
282	Therapeutic drug monitoring of immunosuppressants. , 2020, , 317-332.		0
284	Is the failure of recent trials on withdrawal of calcineurin inhibitors due to inadequate mycophenolic acid dosing?. Journal of Nephrology, 2022, , 1.	0.9	0
285	No Influence of Everolimus on Mycophenolic Acid Area Under the Concentrationâ€“Time Curve: Limited Sampling Strategy for Mycophenolic Acid in Japanese Kidney Transplant Recipients Treated With Tacrolimus, Mycophenolate Mofetil, Steroid, and Everolimus. Transplantation Proceedings, 2022, 54, 286-292.	0.3	1
286	Twoâ€year outcomes of lowâ€exposure extendedâ€release tacrolimus and mycophenolate mofetil regimen in de novo kidney transplantation: A multiâ€center randomized controlled trial. Clinical Transplantation, 2022, , e14655.	0.8	0
292	Population Pharmacokinetics of Mycophenolic Acid in Renal Transplant Patients: A Comparison of the Early and Stable Posttransplant Stages. Frontiers in Pharmacology, 2022, 13, .	1.6	4
294	Renal Transplantation: Immunosuppression and Managing Allograft Rejection. , 2022, , 1927-1958.		0
295	The combination of exposure to Tacrolimus, mycophenolic acid, Inosine 5â€²â€Monophosphate Dehydrogenase activity and inhibition in the first week define early histological outcomes in renal transplant recipients. Clinical Transplantation, 2022, 36, .	0.8	0
296	Therapeutic Drug Monitoring and Toxicology of Immunosuppressant. , 2022, , 181-196.		0
297	Individualization of Mycophenolic Acid Therapy through Pharmacogenetic, Pharmacokinetic and Pharmacodynamic Testing. Biomedicines, 2022, 10, 2882.	1.4	4
298	Quantitation of Mycophenolic Acid and Mycophenolic Acid Glucuronide in Serum or Plasma by LCâ€MS/MS. Current Protocols, 2023, 3, .	1.3	0
299	Impact of Fasting Status and Circadian Variation on the Pharmacokinetics of Mycophenolate Mofetil and the Glucuronide Metabolite in Renal Transplant Recipients. Transplantation Direct, 2023, 9, e1448.	0.8	0
300	Immunosuppression in Pediatric Kidney Transplantation. , 2023, , 1849-1886.		0
301	Tacrolimus and Mycophenolic Acid Exposure Are Associated with Biopsyâ€Proven Acute Rejection: A Study to Provide Evidence for Longerâ€Term Target Ranges. Clinical Pharmacology and Therapeutics, 2023, 114, 192-200.	2.3	4